Last reviewed · How we verify
Daprodustat small
Daprodustat is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that stabilizes HIF to increase endogenous erythropoietin production and boost red blood cell formation.
Daprodustat is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that stabilizes HIF to increase endogenous erythropoietin production and boost red blood cell formation. Used for Anemia of chronic kidney disease in patients not on dialysis, Anemia of chronic kidney disease in patients on dialysis.
At a glance
| Generic name | Daprodustat small |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | HIF prolyl hydroxylase inhibitor |
| Target | Prolyl hydroxylase domain-containing proteins (PHD) |
| Modality | Small molecule |
| Therapeutic area | Hematology / Nephrology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting prolyl hydroxylase enzymes, daprodustat prevents the degradation of hypoxia-inducible factor (HIF), allowing HIF to accumulate and activate genes involved in erythropoietin (EPO) synthesis. This mimics the body's natural response to low oxygen and stimulates erythropoiesis without requiring exogenous EPO injections. The mechanism is particularly useful in chronic kidney disease where EPO production is impaired.
Approved indications
- Anemia of chronic kidney disease in patients not on dialysis
- Anemia of chronic kidney disease in patients on dialysis
Common side effects
- Hypertension
- Headache
- Diarrhea
- Nausea
- Thromboembolic events
Key clinical trials
- Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF) (PHASE2)
- A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |